Evidence map›Paper›PMID 39939927›Full record

ArticleBMC endocrine disorders2025

Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases.

Daria Lisina, Valeria Mazeeva, Elena Zakharova, Alyona Sorokina, Lilya Dzhemileva, Andrey Grigoriev, Vilen Azizyan, Alexandra Shutova, Ekaterina Pigarova, Larisa Dzeranova and 5 more

Abstract readCase ReportsComparative Study
In one paragraph

Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Daria LisinaEndocrinology Research Centre, Moscow, 117036, Russia.
Valeria MazeevaEndocrinology Research Centre, Moscow, 117036, Russia.
Elena ZakharovaEndocrinology Research Centre, Moscow, 117036, Russia.
Alyona SorokinaEndocrinology Research Centre, Moscow, 117036, Russia.
Lilya DzhemilevaEndocrinology Research Centre, Moscow, 117036, Russia.
Andrey GrigorievEndocrinology Research Centre, Moscow, 117036, Russia.
Vilen AzizyanEndocrinology Research Centre, Moscow, 117036, Russia.
Alexandra ShutovaEndocrinology Research Centre, Moscow, 117036, Russia.
Ekaterina PigarovaEndocrinology Research Centre, Moscow, 117036, Russia.
Larisa DzeranovaEndocrinology Research Centre, Moscow, 117036, Russia.
Galina MelnichenkoEndocrinology Research Centre, Moscow, 117036, Russia.
Sergei RumiantsevEndocrinology Research Centre, Moscow, 117036, Russia.
Natalia MokryshevaEndocrinology Research Centre, Moscow, 117036, Russia.
Vladimir ChekhoninEndocrinology Research Centre, Moscow, 117036, Russia.
Marina LoguinovaEndocrinology Research Centre, Moscow, 117036, Russia. marina.loguinova@mail.ru.

Funding

Ministry of Science and Higher Education of the Russian Federation No. 075-15-2022-310 from 20 April 2022
6 · The paper itself

Abstract

Early detection of aggressive pituitary neuroendocrine tumors (PitNETs) remains challenging due to the absence of reliable markers that can predict disease progression. Aggressive tumors are typically identified through long-term observation. Tumor immune microenvironment (TIME) is crucial for understanding PitNETs' heterogeneity and identifying potential predictors of tumor aggressiveness. In this study, we analyzed immune profile of micro- and macroenvironment in two somatotropinomas (aggressive and non-aggressive) using flow cytometry. We observed lymphopenia and elevated neutrophil levels in the periphery in the patient with tumor recurrence. The aggressive TIME showed greater leukocyte infiltration, with lymphoid cells predominating over myeloid cells along with a higher proportion of CD4 + T cells over CD8 + T cells. We detected double-positive CD4 + CD8 + population, high level of regulatory T cells and a sharp increase in PD-1 + expressing T cells over six months during recurrence. In the blood of the patient with tumor recurrence, we observed reduced granule-mediated cytotoxicity of CD8 + T cells and NK-cells. In the aggressive TIME the number of effector cells producing perforin and granzyme B-both independently and simultaneously was significantly lower. The proportion of CD3-CD20- NK cells and CD3-CD56 + NK cells was low after the first recurrence but increased sharply after six months. The ratio of monocyte subpopulations in tumor differed from that in blood, with CD16 + expressing monocytes predominating in the TIME of both patients. M2 macrophages in TIME rose sharply to 60.8% over six months during recurrence. In several immunological parameters, the patient with tumor recurrence exhibited a more pronounced immunosuppressive profile.

Indexed as

Flow CytometryHuman Growth HormoneNeoplasm Recurrence, LocalNeuroendocrine TumorsPituitary NeoplasmsHumansPrognosisTumor MicroenvironmentHuman Growth HormoneAggressive pituitary neuroendocrine tumorsFlow cytometryImmune microenvironmentPitNETsSomatotropinoma

Identifiers

PMID39939927
PMCPMC11816545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.